Amarin Corporation plc

Amarin Corporation is a global pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. The company's primary focus is its flagship product, Vascepa (icosapent ethyl), a highly purified eicosapentaenoic acid (EPA) derived from fish oil. Vascepa is the first and only prescription treatment approved by the FDA to reduce cardiovascular risk in high-risk patients with persistent elevated triglyceride levels despite statin therapy. Following a significant legal setback in 2020 that invalidated several of its U.S. patents, Amarin has transitioned its business model to focus on global expansion and cost optimization. The company currently operates a direct sales model in the U.S. while utilizing a partnered commercialization strategy for international markets, most notably through a major licensing agreement with Recordati for the European market.